IOL Chemicals and Pharmaceuticals Limited — PPTs, 12-11-2025: Investor Presentation

IOL Chemicals & Pharma delivered strong Q2 & H1 FY26 financial results. Q2 revenue rose 7.9% YoY to ₹567.5 Cr, with profit after tax jumping 56.7% YoY to ₹30.0 Cr. H1 saw revenue grow 8.9% YoY to ₹1,119.2 Cr and profit up 31.0% YoY to ₹64.0 Cr. The Pharmaceuticals segment is a key growth driver, though Q2 sequential profit saw a slight dip from higher fuel costs due to Punjab floods.

The company is strategically shifting focus, with non-Ibuprofen APIs now 34% of pharma revenue, aiming for further expansion and margin growth. Backward integration ensures supply chain resilience. Recent wins include CEP certification for Pantoprazole Sodium, opening doors for exports to Europe, and a new UK subsidiary to boost global reach. Plus, they've launched a new 10,800 MTPA Paracetamol unit and expanded Clopidogrel capacity. Future plans include boosting exports to ~40% and developing 101 acres of acquired land for expansion. #IOLCP #PharmaStocks